| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5581770 | Clinical Lymphoma Myeloma and Leukemia | 2017 | 31 Pages |
Abstract
Although the combination of panobinostat and lenalidomide appears safe in patients with relapsed/refractory HL, the limited efficacy and significant rates of neutropenia and febrile neutropenia observed do not support further evaluation of this combination in HL.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Joseph J. Maly, Beth A. Christian, Xiaohua Zhu, Lai Wei, Jennifer L. Sexton, Samantha M. Jaglowski, Steven M. Devine, Todd A. Fehniger, Nina D. Wagner-Johnston, Mitch A. Phelps, Nancy L. Bartlett, Kristie A. Blum,